Cat. No. 4481
Chemical Name: N-[4-[(6,7-Dimethoxy-4-quinolinyl)o
Biological ActivityInhibitor of c-Fms tyrosine kinase (M-CSFR, CSF1R) (IC50 values are 2, 12, 217 and 451 nM for c-Fms, VEGFR-2, PDGFRβ and c-Kit respectively). Does not inhibit Flt3, EGFR or c-Src. Suppresses osteoclast differentiation and osteolysis in a rat bone metastasis model.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Kubota et al (2009) M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis. J.Exp.Med. 206 1089. PMID: 19398755.
Ohno et al (2007) The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur.J.Immunol. 38 283. PMID: 18085662.
Ohno et al (2006) A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol.Cancer Ther. 5 2634. PMID: 17121910.
If you know of a relevant reference for Ki 20227 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Ki 20227 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Ki 20227, supplier, Ki20227, c-Fms, macrophage, colony-stimulating, factor, receptors, M-CSFR, CSF1R, inhibitors, inhibits, osteolysis, osteoclasts, Tocris Bioscience, Other RTKs Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent and selective PDGFR inhibitorGSK 1363089
Potent inhibitor of MET, VEGFR2, Ron and AXLPF 06273340
Potent and selective pan-Trk inhibitor; peripherally restricted
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.